The Intersectional Viborg Screening Program: Cost-(Effectiveness) of Screening for Diabetes and Cardiovascular Diseases
NCT ID: NCT03395509
Last Updated: 2024-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
4500 participants
OBSERVATIONAL
2014-08-01
2029-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Performance of the Acoustic Based CADScor System in Coronary Artery Disease
NCT06655779
NON-Invasive Examinations of Coronary Artery Disease
NCT00926458
Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease
NCT02264717
Echocardiography in Men With Erectile Dysfunction
NCT05285280
Evaluation of the Functional Impact of Coronary Stenoses in Diabetics by Spectral CT
NCT05471687
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
67 years-old citizens from the surrounding municipalities without the offer of the combined screening are used as a control group (1 case: 5 controls).
There are no exclusion criteria.
The screening examination includes: Blood pressure in both arms, ankle brachial blood pressure index (ABI), ultrasound for carotid plaque and abdominal aortic aneurysm, HbA1c and pulmonary function test. Furthermore, a questionnaire on lifestyle parameters, BMI, medical history, walking-related pain and self-rated quality of life (EQ-5D).
One year after the screening examination, the participants will receive a questionnaire in order to evaluate the effect from a participant perspective. The cost(-effectiveness) of the screening program will be estimated after 5 years based on prevalence of diseases, response rate, data extraction from nationwide registries and existing evidence of disease prevention.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
67 Years
67 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Central Jutland Regional Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Annette Langager Hoegh
MD, PhD, Associated professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Annette Høgh, MD, PhD
Role: STUDY_CHAIR
Steering Committee
Marie Dahl, MSc(nurse)
Role: STUDY_DIRECTOR
Steering Committee
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiovascular research Center (KVC), Viborg Hospital
Viborg, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gras Hojgaard H, Hogh AL, Lindholt JS, Frederiksen K, Dahl M. Effect of nurse-led telephone follow-up to optimize adherence to preventive medication after screen-detected cardiovascular disease: a randomized controlled trial. Eur J Cardiovasc Nurs. 2025 Jul 21;24(5):748-759. doi: 10.1093/eurjcn/zvaf047.
Andersen JW, Hogh A, Lindholt JS, Sogaard R, Stovring H, Yderstraede KB, Sandbaek A, Dahl M. Impact of Population-Based Screening for Diabetes and Prediabetes Among 67-Year-Olds Using Point-of-Care HbA1c on Healthcare Ultilisation, Results from the VISP Cohort. Clin Epidemiol. 2025 Feb 5;17:75-85. doi: 10.2147/CLEP.S487825. eCollection 2025.
Dahl M, Andersen JW, Lindholt J, Krarup NT, Borregaard B, Uberg N, Hogh A. Prevalence of interarm blood pressure difference is notably higher in women; the Viborg population-based screening program (VISP). BMC Public Health. 2024 Jul 12;24(1):1868. doi: 10.1186/s12889-024-19388-8.
Hogh A, Lindholt JS, Sogaard R, Refsgaard J, Svenstrup D, Moeslund NJ, Bredsgaard M, Dahl M. Protocol for a cohort study to evaluate the effectiveness and cost-effectiveness of general population screening for cardiovascular disease: the Viborg Screening Programme (VISP). BMJ Open. 2023 Feb 28;13(2):e063335. doi: 10.1136/bmjopen-2022-063335.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VISP-dk
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.